China Diagnostic Reagent Market Report, 2007-2009

Oct. 21, 2008 - PRLog -- China's diagnostic reagent industry had lagged behind other countries for a long time. Since 1980s, China's reagent for clinical diagnosis has started entering the industrialization process, following the implementation of China's reform and open-up policy.

From the perspective of current situation in China, China's diagnostic reagent sector is still in its infancy. According to the statistics, China's current diagnostic reagent market size is around CNY3 billion to CNY4 billion, taking up around 1/14 of the global market. Though China's diagnostic reagent sector is just in its early stage, its high rate of profit return is a major factor to lure many investors into entering the market. Long-term competition in the sector has scaled largely down the number of companies. At present, the sector has a high degree of market concentration in key products. A group of powerful companies, such as Wantai Biological Pharmacy Enterprise Co., Ltd., Shanghai Kehua Bio-engineering Co., Ltd. and Kinghawk Pharmaceutical Co., Ltd., with good performance in R&D and production has developed rapidly, grabbing a considerable market share.

Clinical practice in the developed countries shows that diagnostic expenditure accounts for 20% to 30% of the total medical expenditure. But the ratio in China is less than 10%, indicating a huge market is to be exploited. It is forecast that China's vitro diagnostic reagent market will grow at a rate of around 20%. Opportunities are always accompanied by challenges. The development of China's diagnostic reagent sector in the next five years is still unknown, but it is well worth expecting.

Market value of diagnostic reagent increases faster than its output. Shifting from traditional microbiological test method to quick test method is the driver of the rapid growth of diagnostic reagent market. As for these new test methods, each of diagnostic reagents is of a higher price, but it is becoming more popular, as it is convenient and results come out faster than the traditional method. At present, the traditional test method with a total of 963 million doses takes up 79.8% of market share, and the quick test method with a total of 232 million doses, including convenient reagent, immunity reagent and molecule reagent, takes up 20.2% of market share.  

In 2008, the quick test method will grow exponentially, and the market share of the traditional test method is expected to drop to 69.4% in the full year. Each of reagents of the quick test method will have a considerable growth in the next five years and by then their annual output will be doubled on the basis of the current output. As the average price of the quick test reagent is higher than the traditional test reagent, so rises in prices will be more evident than increases in production.

Table of content

1. China's Diagnostic Reagent Market in Globalization Process
1.1 Impact of Globalization on China's Medicine Market
1.2. Safety Factors of Economic Globalization, 2009

2. Industrialization of Reagent for Clinical Diagnosis
2.1 Present Situation of China's Diagnostic Reagent Sector
2.2 Prospect of China's Diagnostic Reagent Market
2.3 Scale of China's Diagnostic Reagent Market
2.4 China's Diagnostic Reagent Producers
2.5 Countermeasures of China's Diagnostic Reagent Sector

3. Clinical Diagnostic Reagent R&D
3.1 Development of Medical Inspection and Reagent for Clinical Diagnosis
3.2 Main Reagents for Clinical Diagnosis

4. China's Diagnostic Reagent Market in 2008
4.1 Production Capacity of China's Diagnostic Reagent Sector
4.1.1 Producers
4.1.2 Market Size
4.1.3 Research and Development
4.2 Segmented Market
4.3 Market Capacity
4.4 Hospital Channels
4.4.1 Policy and Mode of Purchasing Medicine with Central Bidding
4.4.2 Hospital's Procurement and Management of Diagnostic Reagent

5. Segmented Market of Diagnostic Reagent
5.1 Cardiovascular Diagnostic Reagent
5.1.1 Background and Reasons of Cardiovascular Disease
5.1.2 Relationship between Nutrition and Cardiovascular Disease
5.1.3 Genetic Revolution of Cardiovascular Diagnosis
5.1.4 Incidence of Cardiovascular Disease
5.1.5 New Stage of Cardiovascular Disease Prevention
5.1.6 New Mode of Cardiovascular Disease Prevention
5.1.7 Market of Test Reagent for the Detection of Cardiovascular Disease
5.2 Venereal Diagnostic Reagent
5.2.1 AIDS Incidence in China
5.2.2 Anti-AIDS Medicine Market
5.2.3 Incidence Rate of Venereal Disease and Morbidity Situation
5.2.4 Market Capacity of Venereal Disease Test Reagent
5.3 Hepatitis Diagnostic Reagent
5.3.1 Market of Test Reagent for the Detection of Hepatitis
5.4 Test Reagent for the Detection of Tumor
5.4.1 Tumor Markers and Clinical Application
5.5 SARS Diagnostic Reagent R&D
5.6 HTLV Market and HTLV R&D
5.6.1 Introduction of HTLV

6. China's Diagnostic Reagent Import and Export
6.1 Import and Export
6.2 Global Diagnostic Reagent Export Structure
6.3 Regional Structure of Diagnostic Reagent Export in China
6.4 Trade Mode

7. Diagnostic Reagent Producers
7.1 Overall Situation
7.2 Roche
7.3 Abbott
7.4 Johnson and Johnson
7.5 GlaxoSmithKline
7.6 Pfizer

8. Domestic Key Enterprises, 2008-2009
8.1 FOSUN Pharmaceuticals (Group) Corporation
8.2 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
8.3 Shanghai Rongsheng Biotech Co., Ltd.
8.4 Shanghai Kehua Bio-engineering Co., Ltd.
8.5 Nanjing Jiancheng Bioengineering Institute
8.6 Livzon Syntpharm Co., Ltd. (Zhuhai FTZ)
8.7 Joint Ventures
8.8 Import Agents

9. Development Trend of China's Diagnostic Reagent in 2009
9.1 Chinese Government Pays Much Attention To Developing Diagnostic Reagent
9.2 Prospect of China's Diagnostic Reagent Development in 2009
9.2.1 Profitability and Growth of Diagnostic Reagent Sector
9.2.2 Factors Affecting Development of Diagnostic Reagent Market
9.2.3 Development Trend of Diagnostic Reagents in 2009
9.2.4 Forecast of Output Value of Industrial Microbiological Test Reagents
9.2.5 Market Prospect of Vitro Diagnostic Reagents in 2009
9.2.6 Market Prospect of Diagnostic Reagent for Diabetes in 2009
9.2.7 Market Prospect of Anti-AIDS Medicine in 2009
9.2.8 Development Prospect of China Biopharmaceutical Market
9.2.9 Development Trend of Key Biopharmaceutical Technology in 2009

10. Strategies for Entering Diagnostic Reagent Market in 2009
10.1 Countermeasures about Products
10.2 Countermeasures about Market Competition
10.2.1 Capacity Expansion by Mergers and Restructuring
10.2.2 Regional General Distribution System
10.2.3 Targeting the International GMP Pass
10.3 Market Entry Procedure and Investment in the Market
10.3.1 Product Quality Standards and Market Entry Examination
10.3.2 Investment in Diagnostic Reagents

11. Technical Environment - Global Biological Technology Market
11.1 Market Prospect
11.1.1 Biological Technology Industry Development
11.1.2 Diagnostic Reagent Market
11.1.3 Forecast of Nucleic Acid Reagent Market
11.2 U.S.A. Market
11.2.1 Number and Size of Biological Technology Companies
11.2.2 R&D Funds in Biological Technology Market
11.2.3 Scale of Consumption

12. Economic Environment - China Biopharmaceutical Industry Development
12.1 Operation of China's Biopharmaceutical Industry in 2007
12.1.1 Changes in Output Value of China Biopharmaceutical Industry in 2007
12.1.2 Changes in the Number of China Biopharmaceutical Companies in 2007
12.1.3 Operation of China Biopharmaceutical Companies in 2007
12.1.4 Asset - Liability of China Biopharmaceutical Companies in 2007
12.1.5 Sales & Expenditure Cost of China Biopharmaceutical Firms in 2007
12.1.6 Profitability of China Biopharmaceutical Companies in 2007
12.1.7 Changes in Ownership Structure of Biopharmaceutical Industry in 2007
12.1.8 Size Structure of China Biopharmaceutical Industry in 2007

# # #

Established in 1999, ResearchInChina is the vertical portal for Chinese business intelligence. Our services are used in a variety of ways, including strategic planning, research report, and as investment research.